Breath Diagnostics’ OneBreath technology will be leveraged to develop a breath analysis test to detect lung cancer. Credit: OpenClipart-Vectors via Pixabay.

Breath Diagnostics has partnered with Mayo Clinic Laboratories to create clinical diagnostic tests that analyse breath samples.

The collaboration aims to identify individual predictive biomarkers for a variety of diseases, including lung cancer. The partners intend to develop a non-invasive, quick and cost-effective test to identify indeterminate pulmonary nodules and monitor for potential recurrence of cancer following surgery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Breath Diagnostics’ OneBreath micro-reactor technology will be leveraged to develop the test. Originally developed by the University of Louisville, OneBreath analyses breath that is exhaled into a 1l non-reactive bag.

“A CT scan can only identify the presence of suspicious pulmonary nodules, and many patients require repeated follow-up CT and PET scans.”

The sample passes through a silicon microreactor chip, which is designed to capture carbonyl compounds generated by cancerous tissues. These compounds are then eluted and assessed using mass spectrometry (MS). Other components in the breath are non-reactive to the chip and pass through the microreactor.

Breath Diagnostics president and CEO Brian Ennis said: “This technology will capture specific cancer biomarkers from a single breath. The test will not expose patients to radiation, and it will provide results in less than 24 hours.

“Some current lung cancer diagnostic tools can be costly. A CT scan can only identify the presence of suspicious pulmonary nodules, and many patients require repeated follow-up CT and PET scans or other invasive follow-up procedures like needle biopsies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our technology is non-invasive and will be a lower cost alternative.”

In 2018, diagnostic company Owlstone Medical raised £11m to develop its Breath Biopsy platform for cancer detection. The system is designed for early disease diagnosis and to enable precision medicine.